Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 14 Sep 2020

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.

Crohn’s disease poses increased myocardial infarction hazard

14 Oct 2019

Patients with Crohn’s disease (CD) appear to be at higher risk of developing myocardial infarction (MI), particularly female and younger patients, a study reports.

The study population included 37,477 individuals newly diagnosed with IBD (mean age, 40.4 years; 56.8 percent male; CD: n=10,708; ulcerative colitis [UC]: n=26,769) and 112,431 matched general population controls. Compared with controls, IBD patients had a higher prevalence of hypertension and dyslipidaemia (12.2 percent vs 11.5 percent and 5.6 percent vs 4.9 percent, respectively; p<0.001).

MI occurred in 146 CD patients vs 244 matched controls (incidence rate [IR], 1.64 vs 0.90 per 1,000 person-years) and in 440 UC patients vs 1,193 matched controls (IR, 1.98 vs 1.78 per 1,000 person‐years).

Multivariable Cox analysis revealed that the risk of MI was significantly higher in CD patients than in controls (hazard ratio [HR], 1.80, 95 percent CI, 1.47–2.21), and this trend was more prominent among patients aged <40 years (IR, 0.69 per 1,000 person-years; HR, 2.96, 1.96–4.47) and among female patients (IR, 2.35 per 1,000 person-years; HR, 2.18, 1.61–2.94).

On the other hand, in the UC group, only women had an elevated MI risk (IR, 2.01 per 1,000 person-years; HR, 1.33, 1.13–1.56).

Researchers explained that the larger effect noted in female IBD patients might be related to the more pronounced role of inflammation in coronary heart disease in women than in men. Specifically, women have a higher level of C‐reactive protein. Likewise, the greater magnitude of increase in cardiovascular risk in younger individuals might be attributed to inflammation levels. [J Am Coll Cardiol 2009;54:1561‐1575; Nat Rev Gastroenterol Hepatol 2015;12:26]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 14 Sep 2020

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.